{"id":66000,"date":"2026-05-22T21:35:47","date_gmt":"2026-05-22T13:35:47","guid":{"rendered":"https:\/\/flcube.com\/?p=66000"},"modified":"2026-05-22T21:35:48","modified_gmt":"2026-05-22T13:35:48","slug":"astellas-and-msds-padcev-keytruda-combination-receives-positive-chmp-opinion-for-muscle-invasive-bladder-cancer-in-eu","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66000","title":{"rendered":"Astellas and MSD&#8217;s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Astellas Pharma Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>)<\/strong> announced that the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> of the <strong>European Medicines Agency (EMA)<\/strong> has adopted a <strong>positive opinion<\/strong> recommending approval of <strong>PADCEV (enfortumab vedotin)<\/strong>, an <strong>Nectin-4 antibody-drug conjugate (ADC)<\/strong>, in combination with <strong>MSD&#8217;s PD-1 antibody Keytruda (pembrolizumab)<\/strong> for the treatment of <strong>adults with resectable muscle-invasive bladder cancer (MIBC)<\/strong> who are <strong>ineligible for cisplatin-containing chemotherapy<\/strong> in the <strong>European Union (EU)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Applicants<\/strong><\/td><td>Astellas Pharma Inc. (TYO: 4503) and MSD (Merck &amp; Co.)<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>PADCEV (enfortumab vedotin) + Keytruda (pembrolizumab)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>Committee for Medicinal Products for Human Use (CHMP), EMA<\/td><\/tr><tr><td><strong>Opinion Type<\/strong><\/td><td>Positive opinion recommending approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neoadjuvant (pre-surgery) and adjuvant (post-radical cystectomy) treatment for resectable MIBC<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Adults ineligible for cisplatin-containing chemotherapy<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>European Union (EU)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-3-ev-303-keynote-905-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase 3 EV-303\/KEYNOTE-905 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (Combination vs. Surgery Alone)<\/th><th>Risk Reduction<\/th><\/tr><\/thead><tbody><tr><td><strong>Event-Free Survival<\/strong><\/td><td>Statistically significant improvement<\/td><td><strong>60%<\/strong><\/td><\/tr><tr><td><strong>Overall Survival<\/strong><\/td><td>Statistically significant improvement<\/td><td><strong>50%<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with prior experience for both agents<\/td><td>Manageable<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Neoadjuvant\/adjuvant combination vs. surgery alone<\/td><td>Randomized, controlled<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>MIBC patients ineligible for or declining cisplatin chemotherapy<\/td><td>High unmet need<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The trial represents a paradigm shift in MIBC treatment, demonstrating unprecedented survival benefits with a perioperative immunotherapy-ADC combination approach in a population historically limited to surgery alone due to cisplatin ineligibility.<\/p>\n\n\n\n<h2 id=\"h-treatment-protocol-amp-innovation\" class=\"wp-block-heading\">Treatment Protocol &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neoadjuvant Phase:<\/strong> PADCEV + Keytruda administered before radical cystectomy<\/li>\n\n\n\n<li><strong>Adjuvant Phase:<\/strong> Continued combination therapy following surgery<\/li>\n\n\n\n<li><strong>Mechanism Synergy:<\/strong> Nectin-4 ADC (PADCEV) targets tumor cells while PD-1 inhibitor (Keytruda) enhances immune response<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> First ADC-immunotherapy combination approved in perioperative MIBC setting<\/li>\n\n\n\n<li><strong>Patient Selection:<\/strong> Addresses critical gap for cisplatin-ineligible patients who represent 30\u201350% of MIBC cases<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-assessment\" class=\"wp-block-heading\">Market Impact Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Addressable Population<\/strong><\/td><td>Estimated 15,000\u201320,000 EU MIBC patients annually ineligible for cisplatin<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Radical cystectomy alone for cisplatin-ineligible patients<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>First perioperative combination therapy for MIBC; no direct competitors in this setting<\/td><\/tr><tr><td><strong>Revenue Potential<\/strong><\/td><td>Combined annual treatment value of \u20ac150,000\u2013\u20ac200,000 per patient<\/td><\/tr><tr><td><strong>Strategic Partnership<\/strong><\/td><td>Strengthens Astellas-MSD collaboration beyond existing indications<\/td><\/tr><tr><td><strong>Global Implications<\/strong><\/td><td>EU approval may influence regulatory decisions in other major markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The positive CHMP opinion positions this combination as a potential new standard of care for cisplatin-ineligible MIBC patients, addressing one of the most significant unmet needs in urothelial cancer treatment.<\/p>\n\n\n\n<h2 id=\"h-forward-commercial-strategy\" class=\"wp-block-heading\">Forward Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing &amp; Reimbursement:<\/strong> Premium pricing expected given substantial survival benefits and high unmet need<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Rapid adoption anticipated due to compelling clinical data and limited alternatives<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Comprehensive launch program targeting urologists, medical oncologists, and surgical oncologists<\/li>\n\n\n\n<li><strong>Diagnostic Development:<\/strong> Potential companion diagnostic strategies to optimize patient selection<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Success may support exploration in other urothelial cancer settings and tumor types<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations. Actual results may differ due to risks including final EMA approval decisions, pricing negotiations, market adoption rates, and competitive developments in the bladder cancer space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,353,29,38,120,2675,176,18,1177],"class_list":["post-66000","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-astellas-pharma","tag-combination-therapy","tag-market-approval-filings","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-pd-1-l1","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas and MSD&#039;s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV (enfortumab vedotin), an Nectin-4 antibody-drug conjugate (ADC), in combination with MSD&#039;s PD-1 antibody Keytruda (pembrolizumab) for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy in the European Union (EU).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66000\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas and MSD&#039;s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV (enfortumab vedotin), an Nectin-4 antibody-drug conjugate (ADC), in combination with MSD&#039;s PD-1 antibody Keytruda (pembrolizumab) for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy in the European Union (EU).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66000\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T13:35:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-22T13:35:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66000#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66000\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas and MSD&#8217;s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU\",\"datePublished\":\"2026-05-22T13:35:47+00:00\",\"dateModified\":\"2026-05-22T13:35:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66000\"},\"wordCount\":498,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Astellas Pharma\",\"Combination therapy\",\"Market approval filings\",\"Merck\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"PD-1\\\/L1\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66000#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66000\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66000\",\"name\":\"Astellas and MSD's PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-22T13:35:47+00:00\",\"dateModified\":\"2026-05-22T13:35:48+00:00\",\"description\":\"Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV (enfortumab vedotin), an Nectin-4 antibody-drug conjugate (ADC), in combination with MSD's PD-1 antibody Keytruda (pembrolizumab) for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy in the European Union (EU).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66000#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66000\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66000#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas and MSD&#8217;s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas and MSD's PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV (enfortumab vedotin), an Nectin-4 antibody-drug conjugate (ADC), in combination with MSD's PD-1 antibody Keytruda (pembrolizumab) for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy in the European Union (EU).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66000","og_locale":"en_US","og_type":"article","og_title":"Astellas and MSD's PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU","og_description":"Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV (enfortumab vedotin), an Nectin-4 antibody-drug conjugate (ADC), in combination with MSD's PD-1 antibody Keytruda (pembrolizumab) for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy in the European Union (EU).","og_url":"https:\/\/flcube.com\/?p=66000","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-22T13:35:47+00:00","article_modified_time":"2026-05-22T13:35:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66000#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66000"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas and MSD&#8217;s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU","datePublished":"2026-05-22T13:35:47+00:00","dateModified":"2026-05-22T13:35:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66000"},"wordCount":498,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Astellas Pharma","Combination therapy","Market approval filings","Merck","Merck Sharp &amp; Dohme","MSD","PD-1\/L1","TYO: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66000#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66000","url":"https:\/\/flcube.com\/?p=66000","name":"Astellas and MSD's PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-22T13:35:47+00:00","dateModified":"2026-05-22T13:35:48+00:00","description":"Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV (enfortumab vedotin), an Nectin-4 antibody-drug conjugate (ADC), in combination with MSD's PD-1 antibody Keytruda (pembrolizumab) for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy in the European Union (EU).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66000#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66000"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66000#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas and MSD&#8217;s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66000"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66000\/revisions"}],"predecessor-version":[{"id":66001,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66000\/revisions\/66001"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}